Overview PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia Status: Completed Trial end date: 2012-07-03 Target enrollment: Participant gender: Summary To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia. Phase: Phase 2 Details Lead Sponsor: Kissei Pharmaceutical Co., Ltd.